- Home
- EXE vs RLAY Comparison
EXE vs RLAY Comparison
Compare EXE & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXE
- RLAY
- Stock Information
- Founded
- EXE 1989
- RLAY 2015
- Country
- EXE United States
- RLAY United States
- Employees
- EXE N/A
- RLAY N/A
- Industry
- EXE
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EXE
- RLAY Health Care
- Exchange
- EXE NYSE
- RLAY Nasdaq
- Market Cap
- EXE 28.3B
- RLAY 576.1M
- IPO Year
- EXE 1993
- RLAY 2020
- Fundamental
- Price
- EXE $109.30
- RLAY $3.63
- Analyst Decision
- EXE Strong Buy
- RLAY Strong Buy
- Analyst Count
- EXE 17
- RLAY 11
- Target Price
- EXE $127.59
- RLAY $18.40
- AVG Volume (30 Days)
- EXE 3.0M
- RLAY 1.6M
- Earning Date
- EXE 08-07-2025
- RLAY 08-05-2025
- Dividend Yield
- EXE 2.24%
- RLAY N/A
- EPS Growth
- EXE N/A
- RLAY N/A
- EPS
- EXE N/A
- RLAY N/A
- Revenue
- EXE $6,568,000,000.00
- RLAY $7,679,000.00
- Revenue This Year
- EXE $159.15
- RLAY $14.31
- Revenue Next Year
- EXE $14.75
- RLAY N/A
- P/E Ratio
- EXE N/A
- RLAY N/A
- Revenue Growth
- EXE 35.62
- RLAY N/A
- 52 Week Low
- EXE $69.12
- RLAY $1.78
- 52 Week High
- EXE $123.35
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- EXE N/A
- RLAY 63.22
- Support Level
- EXE N/A
- RLAY $3.10
- Resistance Level
- EXE N/A
- RLAY $3.75
- Average True Range (ATR)
- EXE 0.00
- RLAY 0.23
- MACD
- EXE 0.00
- RLAY 0.03
- Stochastic Oscillator
- EXE 0.00
- RLAY 84.42
About EXE EXPAND ENERGY CORPORATION
Expand Energy Corp independent natural gas producer in the United States. It is fueling a more affordable, reliable and lower-carbon future. The group focused on developing abundant natural gas, oil, and gas liquids to expand energy access.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).